Cannabis Mental Health Research: Sparse Evidence US Universities
New 2026 research highlights limited evidence cannabis treats anxiety, depression, PTSD. US universities like Johns Hopkins, Yale lead studies on risks for students.
No reviews yet. Be the first to rate Deepak!
Deepak Cyril D'Souza, MBBS, MD is the Vikram Sodhi ’92 Professor of Psychiatry at Yale University School of Medicine and a staff psychiatrist at the VA Connecticut Healthcare System. He received his MBBS from St. John's Medical College in Bangalore, India in 1986 and completed his psychiatric residency at the State University of New York Downstate in 1992, followed by a postdoctoral fellowship in psychopharmacology and neurosciences at Yale University School of Medicine. He joined the faculty in the Department of Psychiatry at Yale and the VA Connecticut Healthcare System, where he has served for more than three decades as a clinician, teacher, and researcher.
He directs the Schizophrenia Neuropharmacology Research Group at Yale (SNRGY), the Neurobiological Studies Unit at the VA Connecticut Healthcare System, the VA-CMHC Schizophrenia Research Clinic, and the Yale Center for the Science of Cannabis and Cannabinoids. His research focuses on the pathophysiology of psychosis and the effects of cannabinoids, employing experimental psychopharmacology, neuroimaging, and clinical trials. He has investigated treatments for schizophrenia, mood disorders, and cannabis use disorder, as well as the therapeutic potential of psychedelic compounds. D'Souza received the Yale Psychiatry residents’ teaching award in 2008 and serves as a principal editor of the journal Psychopharmacology. He chairs the Research and Development Committee at the VA Connecticut Healthcare System and is involved in public education on cannabis and psychosis.
New 2026 research highlights limited evidence cannabis treats anxiety, depression, PTSD. US universities like Johns Hopkins, Yale lead studies on risks for students.